Commonwealth Bank of Australia (OTCMKTS:CSLLY) – Investment analysts at Jefferies Financial Group boosted their FY2020 earnings per share (EPS) estimates for Commonwealth Bank of Australia in a research note issued on Tuesday, November 5th. Jefferies Financial Group analyst D. Stanton now expects that the company will earn $2.42 per share for the year, up from their previous forecast of $2.34. Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Commonwealth Bank of Australia’s FY2021 earnings at $2.79 EPS and FY2022 earnings at $3.24 EPS.
A number of other brokerages have also recently issued reports on CSLLY. ValuEngine cut shares of Commonwealth Bank of Australia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research raised shares of Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research note on Wednesday.
CSLLY stock traded up $0.72 during midday trading on Friday, reaching $90.92. 61,232 shares of the company’s stock traded hands, compared to its average volume of 33,845. Commonwealth Bank of Australia has a 52-week low of $60.89 and a 52-week high of $91.02. The company has a market cap of $81.57 billion, a PE ratio of 42.89 and a beta of 0.68. The company has a current ratio of 2.53, a quick ratio of 1.14 and a debt-to-equity ratio of 0.81. The stock’s 50-day moving average is $84.07.
The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, October 21st. Stockholders of record on Tuesday, September 10th were paid a $0.45 dividend. The ex-dividend date of this dividend was Monday, September 9th. Commonwealth Bank of Australia’s dividend payout ratio (DPR) is presently 41.98%.
Commonwealth Bank of Australia Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Recommended Story: Day Trading
Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.